Radiation therapy (RT) is the single most utilized therapeutic agent in oncology, yet advances in radiation oncology have primarily focused on beam properties. One obvious shortcoming of current clinical practice is that RT is planned without regard to any of the tumor-environmental factors that may influence outcome.
We build mathematical models of radiotherapy for individual patients. We integrate mathematical, computational, biological and clinical sciences to thoroughly investigate tumor growth and response to single or combination therapy. In close collaboration with experimentalists and clinicians, mathematical models that are parameterized with experimental and clinical data can help estimate patient-specific disease dynamics, and predict response to different treatments or treatment protocols.
Tumor-associated antigens, stress proteins, and danger-associated molecular patterns are endogenous immune adjuvants that can both initiate and continually stimulate an immune response against a tumor. In retaliation, tumors can hijack intrinsic immune regulatory programs, thereby facilitating continued growth despite an activated antitumor immune response. Clinically apparent tumors have co-evolved with the patient’s immune system and form a complex Tumor-immune ecosystem.
We combine experimental studies and clinical data to calibrate and rigorously validate mathematical and computational frameworks that simulates the complex adaptive tumor-immune interactions, and how cancer therapies change the tumor-immune ecosystem.
Despite new strategies in “precision medicine” in which the screening or specific therapy is guided by molecular biomarkers, treatment protocols rarely vary between patients. Putative biomarkers are often collected at single time points (such as a genomic profile at biopsy, or cancer stage including tumor size, lymph node involvement, and metastatic load) and are rarely predictive or prognostic.
Our group pioneers the approach to harness patient-specific dynamics as biomarkers for treatment response. With mathematical models describing biomarker dynamics over time, we can make predictions and compare and evaluate clinical responses against the prediction. This identifies actionable triggers for treatment adaptation and quantitative personalized oncology
Dr. Heiko Enderling named Fellow and elected President-elect of the Society for Mathematical Biology
The Society for Mathematical Biology, founded in 1973, promotes the development and dissemination of research and education at the interface between the mathematical and biological sciences. It does so through its meetings, awards, and publications. The Society serves a diverse community of researchers and educators in academia, in industry, and government agencies throughout the world.
Dr. Enderling will begin serving as President-Elect in July, 2020, before assuming Presidency at the SMB annual meeting in July 2021.
EnderlingLab and Shari Pilon-Thomas awarded 5-year NCI U01 award
Drs. Heiko Enderling and Shari Pilon-Thomas have been awarded an NIH/NCI PSOC U01 award for their project "Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy". This project aims to identify radiation fractionations that specifically focus on enhancing immune responses and immune cell infiltration into the tumor as biomarker to predict treatment response.
EnderlingLab receives R21 to predict patient-specific prostate cancer treatment responses
Intermittent androgen deprivation therapy (IADT) is a promising strategy to counteract evolution of resistance in prostate cancer patients. However, successful implementation of IADT requires identification of resistance mechanisms, prediction of responses, and determination of clinically actionable triggers of when to pause and when to resume IADT cycles.
In this work we propose to develop a mathematical framework to explore the contribution of prostate cancer stem cell dynamics to evolving resistance, and to use these dynamics in computer simulations to reliably forecast the response in subsequent treatment cycles on a per patient basis.
Dr. Renee Brady-Nicholls publishes in Nature Communications
Intermittent androgen deprivation therapy (IADT) is an attractive treatment for biochemically recurrent prostate cancer (PCa), whereby cycling treatment on and off can reduce cumulative dose and limit toxicities. Model simulations based on response dynamics from the first IADT cycle identify patients who would benefit from concurrent docetaxel, demonstrating the feasibility and potential value of adaptive clinical trials guided by patient-specific mathematical models of intratumoral evolutionary dynamics.
Published commentary "On the profession of Mathematical Oncology"
Drs. Brady and Enderling publish an opinion article in the Bulletin of Mathematical Biology on the necessary steps for mathematical models to predict novel or optimal cancer theapies. The Brady Pipeline is published open access.
Daniel Glazar presents posters at Society for Neurooncology annual meeting
Congratulations Daniel Glazar on a successful poster presentation at the annual meeting of the Society for Neurooncology (SNO) in Phoenix, AZ.
Daniel, jointly supervised by Dr. Solmaz Sahebjam, presented his work on a novel mathematical dynamics biomarker to predict individual responses to combination therapy in recurrent high-grade glioma patients.